Literature DB >> 19692102

A comparison of the effects of hydromorphone HCl and a novel extended release hydromorphone on arterial blood gas values in conscious healthy dogs.

L A Wunsch1, B K Schmidt, L A Krugner-Higby, L J Smith.   

Abstract

The purpose of this study was to evaluate arterial blood gases in dogs that were given hydromorphone or extended release liposome-encapsulated hydromorphone (LEH). Dogs were randomly administered LEH, n=6, (2.0 mg kg(-1)), hydromorphone, n=6, (0.2 mg kg(-1)) or a placebo of blank liposomes, n=3, subcutaneously on separate occasions. Arterial blood samples were drawn at serial time points over a 6-h time period for blood gas analysis. There was no change from baseline values in P(a)CO(2), P(a)O(2), (HCO(3)-), pH, and SBEc in the dogs that received the placebo. Administration of hydromorphone resulted in significant increases in P(a)CO(2) (maximum (mean+SD] 44.4+1.1mm of Hg) and significant decreases in P(a)O(2) (minimum (mean+SD) 82.4+4.7 mm of Hg) and pH (minimum (mean+SD) 7.31+0.01) compared with baseline. Administration of LEH resulted in significant increases in P(a)CO(2) (maximum (mean+SD) 44.6+0.9 mm of Hg) and significant decreases in P(a)O(2) (minimum (mean+SD) 84.8+2.6mm of Hg) and pH (minimum (mean+SD) 7.34+0.02) compared with baseline. There was no significant difference between these two groups at any time point. The changes observed in P(a)CO(2), P(a)O(2), and pH, however, were within clinically acceptable limits for healthy dogs. LEH was determined to cause moderate changes in arterial blood gas values similar to those caused by hydromorphone. Published by Elsevier India Pvt Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19692102      PMCID: PMC4235959          DOI: 10.1016/j.rvsc.2009.07.008

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  24 in total

Review 1.  Adverse effects of systemic opioid analgesics.

Authors:  S A Schug; D Zech; S Grond
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

2.  Sedative effects and serum drug concentrations of oxymorphone and metabolites after subcutaneous administration of a liposome-encapsulated formulation in dogs.

Authors:  L J Smith; L Krugner-Higby; L A Trepanier; D E Flaska; V Joers; T D Heath
Journal:  J Vet Pharmacol Ther       Date:  2004-10       Impact factor: 1.786

3.  Respiratory depression with opioids.

Authors:  Albert Dahan
Journal:  J Pain Palliat Care Pharmacother       Date:  2007

4.  Postoperative analgesic and cardiopulmonary effects in dogs of oxymorphone administered epidurally and intramuscularly, and medetomidine administered epidurally: a comparative clinical study.

Authors:  N Vesal; P H Cribb; M Frketic
Journal:  Vet Surg       Date:  1996 Jul-Aug       Impact factor: 1.495

5.  Oxymorphone: cardiovascular, pulmonary, and behavioral effects in dogs.

Authors:  V S Copland; S C Haskins; J D Patz
Journal:  Am J Vet Res       Date:  1987-11       Impact factor: 1.156

6.  Pulmonary function in dogs after intercostal thoracotomy: comparison of morphine, oxymorphone, and selective intercostal nerve block.

Authors:  R J Berg; E C Orton
Journal:  Am J Vet Res       Date:  1986-02       Impact factor: 1.156

7.  Fatal respiratory depression after multiple intravenous morphine injections.

Authors:  Jörn Lötsch; Rafael Dudziak; Rainer Freynhagen; Jürgen Marschner; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Comparative cardiovascular, analgesic, and sedative effects of medetomidine, medetomidine-hydromorphone, and medetomidine-butorphanol in dogs.

Authors:  Wei-Chen Kuo; Robert D Keegan
Journal:  Am J Vet Res       Date:  2004-07       Impact factor: 1.156

9.  Cardiopulmonary effects of sufentanil long acting on sevoflurane anaesthesia in dogs.

Authors:  Ingeborgh Polis; Yves Moens; Dagmar Hoeben; Mulenda Tshamala; Yves Hoybergs; Frank Gasthuys
Journal:  Vet Anaesth Analg       Date:  2006-03       Impact factor: 1.648

10.  Respiratory function during parenteral opioid titration for cancer pain.

Authors:  Bassam Estfan; Fade Mahmoud; Philip Shaheen; Mellar P Davis; Wael Lasheen; Nilo Rivera; Susan B Legrand; Ruth L Lagman; Declan Walsh; Lisa Rybicki
Journal:  Palliat Med       Date:  2007-03       Impact factor: 4.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.